Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available-Reference-Cited by-同舟云学术

Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available

Published:2016-03-22 Issue:9 Volume:34 Page:889-900
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Beauchemin Catherine,Lapierre Marie-Ève,Letarte Nathalie,Yelle Louise,Lachaine Jean

Funder

Canadian Institute for Health Research

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-016-0401-4.pdf

Reference55 articles.

1. Lebwohl D, et al. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009;15(5):386–94.

2. Saad ED, Buyse M. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol. 2012;30(15):1750–4.

3. Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy. Cancer J. 2009;15(5):395–400.

4. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13(Suppl 2):19–21.

5. US Department of Health and Human Services: Food and Drug Administration: Center for Drug Evaluation and Research (CDER): Center for Biologics Evaluation and Research (CBER), Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville: Food and Drug Administration (FDA); 2007. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf . Accessed Dec 2015.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature;JNCI Monographs;2022-07-01

2. Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence;Health Economics;2022-05-24

3. What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population;Applied Health Economics and Health Policy;2019-07-30